The long game: Precision trials shouldn’t start from zero every time

Precision medicine sponsors invest heavily to identify, educate, screen, consent, genotype, and support rare patients. In many programs, once a trial ends, that infrastructure does not persist. Patient relationships become inactive, data remains fragmented across systems, and subsequent programs rebuild from the beginning.

In precision medicine, patient engagement done well creates a reusable data and relationship layer that compounds in value across trials, registries, long-term follow-up, and future development programs.

Patient engagement therefore functions as more than a driver of trial performance. It defines whether each program contributes to a growing, reusable patient asset or remains a one-time effort.

A lifecycle approach to engagement enables sponsors to improve enrollment timelines, increase retention, enhance data quality, and build patient infrastructure that supports ongoing development.

What is patient engagement in precision medicine trials

Patient engagement in this context refers to structured, ongoing interaction between sponsors and participants across every stage of a clinical program. It includes:

• Awareness and education prior to recruitment
• Pre-screening and eligibility confirmation
• Enrollment and participation during the study
• Retention through study completion
• Re-engagement for future trials

This model aligns engagement with both operational performance and data generation. In precision medicine, participation is closely tied to the collection of genomic and longitudinal data. Sustained engagement ensures that these data are complete, reliable, and usable for both current and future studies.

Why engagement must extend beyond recruitment

Engagement drives measurable trial outcomes

Participant experience is increasingly recognized as an important factor in clinical trial performance. Research from the Tufts Center for the Study of Drug Development has shown that patient burden, including complexity of protocols and frequency of visits, is associated with higher dropout rates and lower retention. Another study indicates that improved communication and patient-centric trial design can support adherence and study completion.

Within Sano-supported programs, high clarity in digital workflows and positive participant feedback are observed alongside strong pre-screening completion, consent rates, and overall study progression. These observations are consistent with broader industry findings that reducing friction in the participant journey can support more efficient trial execution.

These relationships establish engagement as a measurable input into trial efficiency rather than a secondary consideration.

Early disengagement creates downstream inefficiency

Attrition often begins before enrollment. Complex workflows, unclear communication, and delays in eligibility confirmation reduce conversion at each stage of the funnel.

In precision medicine trials, this issue is amplified by the need for genetic validation. If engagement is not optimized, patients who begin the process may not complete testing or progress to enrollment, reducing overall yield and increasing cost per eligible participant.

Engagement influences long-term development value

High-quality engagement extends beyond a single trial. Participants who have a positive experience are more likely to remain engaged over time and participate in future studies. In practice, a significant proportion of participants in Sano-supported programs indicate willingness to be re-contacted for subsequent trials, enabling the creation of reusable recruitment cohorts.

This creates a reusable, permissioned cohort that supports ongoing development rather than a single study outcome.

The engagement lifecycle

1. Identification and awareness

The first stage of engagement determines whether eligible patients enter the recruitment funnel.

In precision medicine, many patients are not visible through traditional clinical pathways. They may be undiagnosed, misdiagnosed, or geographically distant from specialist centers. Engagement strategies must therefore extend beyond site-based recruitment to include:

• Digital outreach tailored to specific patient populations
• Partnerships with patient advocacy organizations
• Educational content that increases awareness of research opportunities

At this stage, engagement establishes trust and creates access.

2. Pre-screening and eligibility confirmation

Pre-screening is a critical conversion point in the trial lifecycle.

Clear, structured workflows improve completion rates and reduce early attrition. Digital platforms that guide participants through eligibility questions and consent processes can significantly increase conversion through the enrollment funnel.

Genetic testing introduces both an opportunity and a constraint. It enables precise identification of eligible patients, but it also adds complexity to the participant journey. Engagement strategies must therefore reduce friction by providing:

• At-home testing options
• Clear communication about process and timelines
• Access to genetic counseling

In variant-driven Parkinson’s disease programs supported by Sano, early engagement combined with streamlined genetic testing enabled rapid identification of eligible participants within weeks of campaign launch. High completion rates at this stage ensured that patients progressed efficiently into the clinical workflow.

3. Enrollment and participation

Once eligibility is confirmed, engagement determines how quickly and effectively patients enter the study.

In the genetically stratified Parkinson’s programs mentioned above, a high proportion of genetically confirmed participants were successfully referred to trial sites. This reflects a system in which engagement is integrated across outreach, testing, and referral rather than treated as separate processes.

Embedding engagement within clinical sites further improves conversion. When site teams are equipped with clear referral pathways and integrated testing workflows, patient identification becomes part of routine care. This approach has been shown to increase the proportion of randomized participants originating from activated sites and to support consistent enrollment.

4. Retention and study completion

Retention reflects sustained engagement across the study lifecycle.

Participants who understand the study, feel supported throughout the process, and experience minimal friction are more likely to complete the trial. This leads to:

• Higher protocol adherence
• More complete datasets
• Greater continuity across study milestones

In precision medicine trials, where each participant represents a highly specific data point, maintaining engagement through completion is essential.

5. Re-engagement and cohort reuse

The final stage of engagement extends beyond the individual trial.

Participants who have completed one study can be re-engaged for future programs, particularly when they have already undergone genetic testing and provided longitudinal data. This creates a reusable, permissioned cohort that can be activated for new studies with reduced acquisition cost and shorter timelines.

Reusable cohorts enable:

• Faster recruitment for future trials
• Natural history studies and registries
• Long-term follow-up and post-approval research
• Label expansion programs
• Portfolio-level planning across indications

Re-engagement transforms patient recruitment into a cumulative asset. Each interaction strengthens the overall dataset and expands the pool of accessible participants.

Engagement as a signal system

From screening volume to eligibility signal quality

Traditional recruitment models often prioritize volume metrics such as the number of patients screened or tests conducted. In precision medicine, these metrics do not reliably predict success.

What matters is the quality of the eligibility signal. This refers to the proportion of patients who meet protocol criteria after genetic and clinical validation.

In programs supported by Sano, high eligibility signal quality enables sponsors to scale recruitment confidently. When early data demonstrated strong match rates, testing capacity was increased during the program because each additional participant screened had a high probability of meeting eligibility criteria.

This approach shifts the focus from activity to outcome.

How engagement improves signal quality

Engagement plays a role in shaping eligibility signals by influencing how participants move through the funnel.

• Clear communication increases completion of pre-screening and testing steps
• Efficient workflows reduce delays between stages
• Trust encourages participants to provide accurate and complete information

These factors improve the accuracy of patient identification and increase the likelihood that screened participants will meet protocol criteria.

Technology and infrastructure for lifecycle engagement

Effective engagement at scale requires integrated technology and operational infrastructure.

Key components include:

• Digital platforms that guide participants through each stage of the journey
• Real-time data integration across genomic, clinical, and patient-reported sources
• Secure systems for data sharing and interoperability
• Tools for communication, education, and ongoing engagement

Integration across systems is essential for creating a comprehensive view of each participant and enabling consistent decision-making across the trial lifecycle. Interoperability and secure data sharing are particularly important for maintaining trust and ensuring compliance.

Measuring engagement across the lifecycle

To operationalize engagement, sponsors must define and track relevant metrics.

These include:

• Pre-screening completion rates
• Consent completion rates
• Time to genetic confirmation
• Referral and enrollment rates
• Retention and study completion rates
• Re-engagement rates

Engagement metrics provide early indicators of trial performance and enable continuous optimization. High email open rates, strong response cycles, and willingness to participate in future studies all signal a healthy engagement system and a sustainable recruitment model.

Conclusion

For sponsors developing precision medicines, the question has become larger than whether patient engagement improves a single trial. It is now whether each program leaves behind infrastructure that makes the next one faster, smarter, and less wasteful. The sponsors that treat engagement as a reusable data and relationship layer will be better positioned to recruit, learn, recontact, and scale across their portfolios.